Inovio Pharmaceuticals vs Kazia Therapeutics
INO and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INO and KZIA compare
Kazia Therapeutics grew revenue faster over the last twelve months (−98.2% versus −100% for Inovio Pharmaceuticals).
Inovio Pharmaceuticals scores higher on the StockData Score (4 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INO | KZIA |
|---|---|---|
| Size and price | ||
| Market cap | $169M | – |
| Share price | $1.63 | $5.31 |
| Change, 1 year | −20.5% | −15.3% |
| Change, 5 years | −98.1% | −98.9% |
| Beta (5Y) | −0.26 | 4.08 |
| Employees | 27 | 14 |
| StockData Score | ||
| Total score | 4 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 38.6× | – |
| FCF yield | −47.9% | – |
| Growth | ||
| Revenue growth (TTM) | −100% | −98.2% (better) |
| Revenue growth, 5Y average | −61.2% | – |
| Profitability | ||
| Net margin | – | −49291% |
| Return on equity | −410% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.00 | 2.87 (better) |
| Altman Z-score | −55.23 | – |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | −22.6% | – |
| Shareholder yield | −22.6% | – |
| Ownership | ||
| Held by institutions | 31.7% | 0.45% |
| Held by insiders | 0.38% | 0.29% |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 21.5% | – |
Go deeper
- INO stock overview
- INO income statement
- INO valuation and score
- KZIA stock overview
- KZIA income statement
- KZIA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.